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Accepted 22 July 2011AbstractObjective: In this study, the Ki-67 proliferative indices among the stages of the endometriosis were compared to clarify whether the proliferation
was increased with increasing disease stage.
Materials and Methods: Thirty-eight patients who underwent surgery either by laparotomy or by laparoscopy with the diagnosis of endome-
triosis and 21 patients, as controls, who underwent hysterectomy with the diagnosis of myoma uteri and without any endometrial pathology at
our hospital between 2005 and 2007 were studied. Biopsy specimens of endometriotic foci and endometriomas in study group, and eutopic
endometrium of hysterectomy specimens of control group were studied.
Results: Fifty-nine patients were divided into Group 1 (21 patients in control), Group 2 (19 patients in stage I and II of endometriosis), and Group
3 (19 patients in stage III and IV). A moderate correlation between the stage of endometriosis and the degree of Ki-67 staining was found. When
Ki-67 immunohistochemical staining was considered according to the threshold value for CA-125 (35 U/mL), Ki-67 positivity was increased
with the increase in CA-125 value, but this increase was not statistically significant.
Conclusion: Endometriosis shows some characteristics of tumors such as high rate of invasion, getting autonomy, and proliferation as the disease
progresses with subsequent damage to target organs. When the stage of the disease increases, environment becomes more suitable for increased
proliferation and invasion. In this study, the increase in proliferative activity as the severity increases is shown by the increase in Ki-67 index. As
more studies are being conducted in this field, pathogenesis will be clarified, which could help in the development of new treatment modalities.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Endometriosis is a chronic, estrogen-dependent gyneco-
logical disorder characterized by the presence of functional
endometrial glands and stromal elements outside the uterus,
which induces chronic, inflammatory reaction associated with
complaints ranging from pelvic pain to infertility [1e6].* Corresponding author. Tevfik Saglam Caddesi Emlakbankası Evleri, C3
Blok No: 32, Etlik, Ankara 06020, Turkey.
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http://dx.doi.org/10.1016/j.tjog.2012.07.013Although it is thought to be hormone dependent, there are
many theories to explain the pathogenesis: retrograde
menstruation, lymphatic and hematogenous spread, immuno-
logic theory, genetic factors, and environmental factors.
Ki-67 is a nuclear antigen present only in proliferating cells
except G0 phase of cell cycle. Increase in antigenic expression
during cell cycle in both benign and malignant cell lines
assessing their proliferative status has also been shown [7e9].
Ki-67 score is now used to predict the prognosis, survival, and
even the recurrences. A high level of Ki-67 proliferative index
(PI) is associated with aggressive tumoral behavior and
metastasis [10e19].cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Characteristic features of the groups.
Control (n ¼ 21) Stage I and II
(n ¼ 19)
Stage III and
IV (n ¼ 19)
P value
Age (y) 44.5  4.1 41.4  7.3 42.1  6.3 0.238a
Gravidity 3.7  2.0 3.2  2.5 2.4  2.3 0.077b
Parity 2.4  1.3 2.3  1.6 1.8  1.2 0.282 b
CA-125 17.7  6.3 41.6  35.1 86.6  111.5 <0.001b
CA19-9 10.5  9.4 26.3  23.0 40.3  44.5 <0.001b
a One-way variance analysis.
b KruskaleWallis test (Bonferroni post hoc test).
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Mu¨llerian epithelia. Elevated serum levels have also been recog-
nized in gynecologicmalignancies in patientswith endometriosis.
CA19-9, a carbohydrate antigen, is elevated in gastroin-
testinal adenocarcinomas, and pancreatic and ovarian tumors.
Like serum CA-125 levels, serum CA19-9 levels seem to be
elevated in endometriosis patients [20].
Although it is thought to be a hormone-dependent disease, few
recent studies investigating the invasive phenotype of endome-
triosis resembling the tumors draw attention toKi-67 [21e23]. In
this study, we compared the Ki-67 PIs at different stages of the
endometriosis to clarify whether the proliferation was increased
with increasing stage and its correlation with tumor markers.
Materials and methods
Thirty-eight patients who underwent surgery for endome-
triosis (either by laparotomy or by laparoscopy) and 21 patients
who underwent hysterectomywith the diagnosis ofmyoma uteri
and without any endometrial pathology at our hospital between
2005 and 2007 were studied. Among the 38 patients in the study
group, categorized according to the revised American Fertility
Society (r-AFS) classification, 19 patients were at stage I and II
and remaining 19 were at stage III and IV. Diagnosis of endo-
metriosis was established following both macroscopic and
postoperative histologic confirmation. Biopsy specimens of
endometriotic foci and endometriomas of the study group and
eutopic endometrium of hysterectomy specimens of the control
groupwere studied. All patients were operated at early follicular
phase of menstrual cycle. Blood samples for tumor markers
were also taken at early follicular phase of the menstrual cycle.
Patients had not been treated with any hormonal agent. The
Ethics Committee of the hospital has also approved this study.
Specimens were fixed with 10% formalin, sent to pathology
laboratory, and embedded in paraffin blocks. Five-micron-thick
serial sections were made and studied after staining the speci-
mens with hematoxylin and eosin. Immunohistochemical
analysis was performed by means of indirect bio-
tinestreptavidin-amplified system, using DAKO immuno-
staining kit and Ki-67 MiB1 antibodies. Briefly, deparaffinized
sections were washed with phosphate buffer saline (PBS)
solution, heated for 5 minutes in Antigen AR 10 solution at
700W three times in a microwave, and washed with PBS again.
Ki-67 MIB-1 antibodies, link antibodies, and labeling reagents
were applied after they were washed with PBS each time.
Degree of positive staining was calculated by counting 100
endometrial epithelial cells: 0e5 cells with nuclear staining
were evaluated as negative, 6e25 cells as (þ), 26e50 cells as
(þþ),51e75 as (þþþ), and 76 and more as (þþþþ). All
specimens were examined by the same pathologist.
Results
Fifty-nine patients were divided into group 1 (21 patients in
control), group 2 (19 patients in stage I and II), and group 3
(19 patients in stage III and IV). Characteristic features of the
groups are shown in Table 1. Mean serum concentration ofCA-125 was 17.7  6.3 U/mL in control group, 41.6  35.1
U/mL in group 2, and increased to 86.6  111.5 U/mL in
group 3. The difference between the mean values was statis-
tically significant ( p < 0.001). When the groups were
compared in pairs, the only statistically significant difference
was detected between the mean values of CA-125 of control
group and that of group 3 ( p < 0.001), but not between group
1 and 2 or between group 2 and 3. Mean concentration of
serum CA19-9 values in control group, group 2, and group 3
were 10.5  9.4, 26.3  23, and 40.3  44.5 U/mL, respec-
tively. The difference between the mean values was statisti-
cally significant ( p < 0.001, KruskaleWallis test). When post
hoc tests were performed, differences between the mean
CA19-9 values of control group and group 2 ( p < 0.01) and
between those of control group and group 3 ( p < 0.001) were
found to be statistically significant, but no significant differ-
ence was found between early stages and late stages of
endometriosis (group 2 and 3).
Table 2 shows the Ki-67 immunoreactivity distribution in the
groups. It was interesting that neither 3(þ) nor 4(þ) staining was
found in group 1 and group 2, and negative staining percentages
were similar in those groups (71.4% and 73.7%, respectively).
Also distribution of Ki-67 staining between group 1 and 2 is not
statistically significant ( p ¼ 0.669).
The distribution in group 3 is very different. Three cases
(15.8%) were stained as 4(þ) four cases (21.0%) were stained
as 3(þ), and three cases (15,8%) had negative staining. As
group 1 and 3 were compared, a statistically significant
difference was found ( p ¼ 0.004). The difference was due to
the high rate of the negatively stained cases in group 1.
When group 2 and 3 were compared, the most noticeable
finding was that 14 patients (73.7%) in group 2 and three
patients (15.8%) in group 3 were found to be not stained. The
difference between these groups was statistically significant
( p ¼ 0.001). A moderate correlation was found between the
stage of endometriosis and the degree of Ki-67 staining
(r ¼ 0.5, p < 0.001, Spearman correlation analysis).
As shown in Table 3, when Ki-67 immunohistochemical
staining was distributed according to the threshold value for
CA-125 (35 U/mL), no statistical difference was found in the
staining distribution between below and above threshold levels
of serum CA-125 ( p ¼ 0.561, dual-sampling Kolmogor-
oveSmirnov test). Also, no statistically significant difference
was observed between positive and negative staining
(according to the distribution below and above threshold level)
( p ¼ 0.113, chi-square test). However, when a correlation
Table 2
Ki-67 proliferative index distribution according to the groups.*
Ki-67 Control Stage I and II Stage III and IV
Negative 15 (71.4%) 14 (73.7%) 3 (15.8%)
1þ staining 4 (19.1%) 2 (10.5%) 6 (31.6%)
2þ staining 2 (9.5%) 3 (15.8%) 3 (15.8%)
3þ staining d d 4 (21.0%)
4þ staining d d 3 (15.8%)
*Pearson chi-square test, p ¼ 0.002.
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positivity was increased, but this increase, although very
close, was not statistically significant (r ¼ 0.256, p ¼ 0.051).
Discussion
The etiopathogenesis of endometriosis, which is common
in infertile population, is largely unknown [24e27]. Chronic
and recurrent progress, proliferative, infiltrative and invasive
phenotype of the lesions shares the similar aspects of tumoral
process [28e30]. This new perspective creates an interest on
Ki-67 monoclonal antibody. Ki-67 is a nuclear antigen present
only in proliferating cells. Increase in antigenic expression,
meaning high Ki-67 PI, is associated with aggressive tumoral
behavior and metastasis [7e19].
Li et al compared the PI of eutopic and ectopic endometrial
cells. PI of endometriotic cells was found to be constantly higher
than normal endometrium irrespective of the hormonal status
during both menstrual cycle and postmenopause. PI of post-
menopausal ectopic endometriumwas high compared to the low
PI at atrophic endometrium [31]. This supports the hypothesis
that, in addition to hormonal stimulus, proliferation at ectopic
implantation sites is controlled by other factors. The resultswere
supported by Toki et al [32], Nisolle et al [33], and Matsumoto
et al [34]. Park et al [29] observed higher proliferative activity in
the endometrial cells of the patients with endometriosis than in
patients without endometriosis. On the contrary, Jones et al
observed low PI along the cycle of ectopic endometrial cells,
similar to the observations of Suzuki et al [35].
A literature search confirms that our research is the first to
study the relation between the stages of endometriosis andKi-67
PI, although the number of cases is limited. Only Toki et al [20]
studied serum CA-125 and CA19-9 values, degree of immu-
nohistochemical staining of tissue CA-125 and CA19-9, andKi-
67 at endometriosis stage III and IV. They observed a positive
correlation between CA-125 and Ki-67 immunohistochemical
staining, indicating that proliferative (Ki-67 PI high) cells were
actively secreting CA-125. However in our study, as the CA-125
value was increased, Ki-67 positivity was increased, but thisTable 3
Distribution of Ki-67 staining according to the CA-125 threshold value.*
CA-125 value Ki-67 negative Ki-67 (þ) Ki-67 (
Below 35 U/mL 23 (62.1%) 5 (13.5%) 7 (19%
Above 35 U/mL 9 (40.9%) 7 (31.8%) 1 (4.6%
Total 32 (54.2%) 12 (20.3%) 8 (13.6
*Dual-sample KolmogoroveSmirnov test, p ¼ 0.561.increase, although very close, was found to be not statistically
significant (r ¼ 0.256, p ¼ 0.051).
CA-125 is a tumor marker used in diagnosis and follow-up
process, but its sensitivity is low in early stages and use is
limited in late stages [36]. Toki et al could not show any corre-
lation between CA-125 and the disease stage. In our study,
especially in later stages, CA-125 values were significantly
higher than in controls. However, no significant difference was
noted between controls and early stages of the disease, which
supports Toki’s results that CA-125 values do not correlate with
the disease stage. Unlike other studies, we also found a positive
correlation between the endometrial stage and Ki-67 PI. Fifteen
out of 21 patients (71.4%) in control group had no staining, and
only two (9.5%) had 2(þ) staining, for whom noticeable adhe-
sionswere reported during surgery. These two patients likely had
microscopic endometriotic foci that could not be detected during
surgery. In early-stage group (group 2), high rate of negative
staining (73.7%) and absence of 3(þ) and 4(þ) staining were
similar to those in control group,which could be explained by the
hypothesis that proliferation, infiltration, and also invasion are
low in early stages, as characterized by the superficial lesions and
filmy adhesions. But the distribution of Ki-67 PI was completely
different in stage III and IV; as the stage increased, the number of
3(þ) and 4(þ) staining patients was increased. A positive
correlationwas observed between the stage of endometriosis and
the positivity of staining, which indicated that proliferation was
important in the progression of the disease. As the severity of the
disease increases, according to the AFS scores, deep endo-
metriotic lesions, dense adhesions, and cul-de-sac obliteration
are added to the whole picture of the disease. When the etiopa-
thogenesis of the disease is remembered, it is reasonable that
endometrial cells reaching the implantation sites, either via
retrograde menstruation or via hematogen or lymphatic ways,
begin to attach and invade peritoneal surfaces or ovaries. When
the vascularization increases and cytokines are liberated to
environment, invasion deepens.
Gaetje et al [21] showed that cells from peritoneal endo-
metriotic lesions and ametastatic bladder carcinoma cell line had
similar invasion indices, whereas normal endometrial cells and
nonmetastatic cells were noninvasive. They also studied E-cad-
herin expression of the cells from biopsies of endometriotic
lesions and endometrium [22]. E-cadherin is an invasion
suppressor molecule found in epithelial cells holding them
together. In vitro invasive endometriotic cells were shown to be
E-cadherin-negative nonmalignant cells; E-cadherin-negative
cell fraction was increased in sections of endometriotic lesions
but not in the eutopic endometrium. It has been proposed that
these E-cadherin negative cells migrate to ectopic locations
in vivo, which is important in pathogenesis.þþ) Ki-67 (þþþ) Ki-67 (þþþþ) Total
) 1 (2.7%) 1 (2.7%) 37 (100%)
) 3 (13.6%) 2 (9.1%) 22 (100%)
%) 4 (6.8%) 3 (5.1%) 59 (100%)
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increasing the invasive potential. They have shown that
cytokeratin-positive and E-cadherin-negative endometriotic
cells have an invasive phenotype in vitro, similar to metastatic
carcinoma cells; the invasiveness of endometriotic cells can be
stimulated by a heat-stable protein present in peritoneal fluid
but not the eutopic endometrial cells.
In summary, when the stage of the disease increases, prolif-
eration is increased. The increase in activity as the severity of
disease increases is shown by an increase in the Ki-67 index.
When the cells increase their proliferative potential, they get
autonomy as the tumoral cells. They attack the adjacent tissue, and
at the end dense adhesions occur and anatomy is distorted. Post-
menopausal endometriosis cases and increases in bcl-2, a gene
that suppresses the cell death, and Ki-67 prove this autonomy [23,
32]. Although it is regarded as hormone dependent, endometriosis
shows some characteristics of tumors such as high rate of invasion,
getting autonomy and proliferation, and subsequent damage to
target organs with the progression of the disease. With more
studies being conducted in this field, pathogenesis will be clarified
and perhaps new treatment modalities could be developed.References
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